GERN
Geron Corporation
There isn't enough reported data to score GERN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GERN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GERN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GERN PE Valuation
GERN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 19x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GERN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
GERN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GERN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.08 | +$0.04 |
| Q2 2026 | -$0.11 | +$0.02 |
| Q1 2026 | -$0.11 | +$0.10 |
| Q4 2025 | -$0.13 | +$0.14 |
| Q3 2025 | -$0.12 | +$0.19 |
| Q2 2025 | -$0.13 | +$0.22 |
| Q1 2025 | -$0.21 | +$0.13 |
| Q4 2024 | -$0.27 | +$0.05 |
GERN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GERN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $60.2M | +27% |
| Q2 2026 | $57.5M | +17% |
| Q1 2026 | $51.8M | +31% |
| Q3 2025 | $47.2M | +67% |
| Q2 2025 | $49M | +5460% |
| Q1 2025 | $39.6M | +12927% |
| Q3 2024 | $28.3M | +17138% |
| Q2 2024 | $882K | +2941% |
HIMS has the stronger quarterly revenue trend. Revenue is up 23% for GERN versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | +39 points |
| Q2 2026 | -22% | +3.7 points |
| Q1 2026 | 0.3% | +43 points |
| Q3 2025 | -29% | +70 points |
| Q2 2025 | -25% | +7836 points |
| Q1 2025 | -42% | +18423 points |
| Q3 2024 | -100% | +28932 points |
| Q2 2024 | -7861% | +171281 points |
GERN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GERN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +$23.8M |
| Q2 2026 | -$15.8M | +$11.6M |
| Q1 2026 | -$62.9M | -$14.9M |
| Q4 2025 | -$22.1M | +$21.7M |
| Q3 2025 | -$13.6M | +$45.4M |
| Q2 2025 | -$27.4M | +$26.3M |
| Q1 2025 | -$48M | +$14.9M |
| Q4 2024 | -$43.8M | -$2.8M |
GERN has burned cash in almost every quarter: −$91M over the past year, against −$133M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GERN on cash generation, producing positive trailing cash flow while its opponent burns cash.
GERN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +7.4M shares |
| 1 year | +1.2% | +8.1M shares |
| 3 years | +24% | +130M shares |
| 5 years | +148% | +403M shares |
| Available history | +254% | +484M shares |
GERN has 674M diluted shares, up 1.2% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GERN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GERN Net Leverage
GERN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GERN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 14.7 | Oversold |
GERN's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GERN PE vs Healthcare Sector
GERN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GERN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 11% below |
| 20 week MA | $1.30 | 24% below |
| 50 week MA | $1.38 | 28% below |
| 100 week MA | $1.55 | 36% below |
| 200 week MA | $2.35 | 58% below |
GERN is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GERN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $1.62 | +17% |
| 2021 | $1.62 | $1.37 | -15% |
| 2022 | $1.37 | $2.09 | +53% |
| 2023 | $2.09 | $2.11 | +1% |
| 2024 | $2.11 | $3.35 | +59% |
| 2025 | $3.35 | $1.37 | -59% |
| 2026 YTD | $1.37 | $0.99 | -28% |
GERN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.